Resistance to Anti-VEGF Therapy

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer

3533 Background: Circulating angiogenic factors have been previously shown to be altered in patients (pts) with mCRC on bevacizumab (BV)-containing regimens. However, a systematic evaluation of alterations in levels of the VEGF family of ligands may provide insights into resistance mechanisms. METHODS 42 patients (pts) with mCRC were treated on a single arm phase II study with 5-FU, irinoteca...

Tumor refractoriness to anti-VEGF therapy

Vascular endothelial growth factor (VEGF) has been identified as the most potent cytokine involved in tumor angiogenesis and metastasis formation. Clinical results of anti-angiogenic therapies targeting VEGF and its receptors are very modest, resulting in a moderate improvement of overall survival. The clinical outcome is associated with the development of resistance and the increased risk of i...

Pazopanib and anti-VEGF therapy

Pazopanib (Votrient™, GlaxoSmithKline), a multi-kinase inhibitor with activity against VEGFR and other receptors, was recently approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). Here, we review the history of its development, together with an overview of VEGF and its receptors and co-receptors. Results from selected clinical trial data in RCC and other malignant disea...

ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA Anti-VEGF Therapy For Diabetic Macular Edema

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review

As a progressive chronic disease, age-related macular degeneration (AMD) is the leading cause of irreversible vision impairment worldwide. Experimental and clinical evidence has demonstrated that vascular endothelial growth factor (VEGF) plays a vital role in the formation of choroidal neovascularization. Intravitreal injections of anti-VEGF agents have been recommended as a first-line treatmen...